Biocon, an Indian biopharma company, has expanded its generic formulations portfolio with the US launch of generic Tacrolimus capsules.
Tacrolimus is a calcineurin inhibitor and an immunosuppressant, which was approved last month by the US Food and Drug Administration (FDA) for its use in the treatment of organ transplant patients.
In organ transplant patients, the body’s ability to reject a transplanted organ is reduced.
According to Biocon, Tacrolimus has been effective particularly in the treatment of patients of renal transplant for over 20 years.
Siddharth Mittal – Biocon CEO and Managing Director said: “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”